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Background and purpose: Vesicle-associated membrane-protein-associated protein B
(VAPB) is an endoplasmic reticulum (ER) resident protein participating in ER func-
tion, vesicle traﬃcking, calcium homeostasis and lipid transport. Its N-terminal
domain, named MSP, is cleaved and secreted, serving as an extracellular ligand.
VAPB mutations are linked to autosomal-dominant motor neuron diseases, includ-
ing amyotrophic lateral sclerosis (ALS) type 8. An altered VAPB function is also
suspected in sporadic ALS (SALS).
Methods: The expression pattern of VAPB cleavage and secreted products in the
peripheral blood leukocytes (PBL) and cerebrospinal ﬂuid (CSF) of SALS patients
and neurological controls was assessed. PBL from healthy controls were also
analyzed. Assays were carried out through western blotting, using an anti-VAPB
(N-terminal) antibody.
Results: Two VAPB fragments containing the MSP domain (17 kDa and 14 kDa
molecular sizes) were identiﬁed in PBL of SALS and controls, with no signiﬁcant
diﬀerences amongst groups. In CSF, only the 14 kDa VAPB MSP fragment was
expressed and a corresponding VAPA fragment was not detected. The CSF VAPB
fragment was absent in 58.7% of SALS patients, of whom 79.2% were bulbar onset
(P = 0.001, bulbar versus spinal).
Conclusions: The absence of the CSF VAPB MSP fragment from most bulbar-
onset SALS patients suggests a speciﬁc alteration of brain-derived VAPB cleavage
and secretion in this group of patients, and hints at a role of VAPB in the patho-
physiology of this motor neuron disease.
Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegen-
erative disease characterized by loss of the upper and
lower motor neurons leading to a progressive muscle
weakness and atrophy [1,2]. Death occurs within a
few years after diagnosis, generally caused by respira-
tory failure [3]. Disease mechanisms are still undeﬁned
and only a few disease-modifying factors have been
identiﬁed that might account for the heterogeneity of
ALS clinical phenotypes [4–6].
Whilst the majority of cases are sporadic ALS
(SALS), about 10% are familial and linked to muta-
tions in diﬀerent genes [7,8]. Amongst these, a muta-
tion in the gene encoding vesicle-associated
membrane-protein-associated protein B (VAPB) has
been described to cause either a slow progressive
ALS, called ALS8, a late-onset spinal muscular atro-
phy, or a severe ALS with rapid progression [9,10].
The VAPB mutation, which results in a proline to
serine substitution at position 56 (p.Pro56Ser), may
behave as a dominant-negative protein ultimately
leading to motor neuron death [9,11].
The recent identiﬁcation of VAPB mutations
(T46I and V234I), with a patient remarkably har-
bouring both VAPBV234I mutation and C9orf72
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repeat expansion, strengthens the association of
VAPB with clinically variable phenotypes [9,10,
12,13], and hints at an important implication of this
protein in motor neuron pathology. Evidence also
suggests that VAPB might have a role in SALS
[14,15].
VAPB belongs to the family of vesicle-associated
membrane-protein-associated proteins, including
VAPA and VAPC, which are endoplasmic reticulum
(ER) resident proteins playing roles in vesicle traﬃck-
ing, bouton formation at the neuromuscular junction,
microtubule organization, calcium homeostasis, lipid
transport and unfolded protein response [16,17]. Stud-
ies entail p.Pro56Ser mutation in an abnormal reorga-
nization of ER structure causing altered unfolded
protein responses and formation of insoluble aggre-
gates [14,18–20].
There is evidence that VAPB undergoes proteolysis
in rodent neuronal cells and human leukocytes
[11,21,22]. The N-terminal domain, named MSP
because of the homology with the major sperm protein
from nematodes [16], can be secreted and found in
human serum [11]. The secreted MSP fragment may
act as an extracellular signal at selective post-
synaptic receptors with a role in motor neuron survival
and muscle function [11,23]. Of interest, p.Pro56Ser
protein does not undergo proteolysis [11,22].
In this study, the expression of VAPB processing
products in peripheral blood leukocytes (PBL) and
cerebrospinal ﬂuid (CSF) of patients with SALS was
analysed. Two VAPB fragments containing the MSP
domain were found in leukocytes and one in CSF,
whereas the same expression pattern was not detected
for the homologous VAPA. The PBL expression of
the two VAPB fragments was similar in SALS
patients and controls, which included healthy and
neurological controls. Conversely, the expression of
CSF VAPB MSP fragment was absent in most bul-
bar-onset SALS patients, suggesting an abnormal
brain-derived VAPB processing and secretion.
Materials and methods
Subjects
Forty-six non-demented SALS patients (21 men, 25
women; M/F = 0.84) were diagnosed according to the
revised El Escorial/WFN criteria [24]. All patients
were on riluzole therapy. None was with percutaneous
endoscopic gastrostomy or under non-invasive ventila-
tion at the time of CSF or blood drawing. Biological
samples were taken at the time of the diagnostic
work-up for each ALS patient enrolled. All patients
belonged to stage 2A (n = 18, 39.1%) or stage 2B
(n = 28, 60.9%), according to the staging system pro-
posed by Roche et al. [25].
Twenty-two patients presented as spinal onset
(47.8%), whereas the remaining 24 were bulbar onset
(52.2%). Patients were submitted to a 30-ml blood
drawing for PBL puriﬁcation and a lumbar puncture.
Disease progression was rated at 3-month intervals
with the clinimetric Appel ALS rating scale (AARS)
[26]. At least three evaluations with AARS were con-
sidered suﬃcient to establish the rate of disease pro-
gression (i.e. slow, intermediate and rapid course).
Controls were age and sex matched to cases and
consisted of 11 healthy subjects and 33 patients with
neurological disorders not involving primarily motor
neurons: Tapia’s syndrome (n = 1); depressive disor-
der (n = 2); cervical spondylotic myelopathy (n = 4);
non-inﬂammatory polyneuropathy (n = 7); conversion
disorder (n = 4); Alzheimer dementia (n = 5); multiple
sclerosis (n = 3); spinocerebellar ataxia (n = 2); pri-
mary progressive aphasia (n = 3); normal pressure
hydrocephalus (n = 2).
The demographic and clinical characteristics of the
ALS patients and control groups are summarized in
Table 1.
This study was approved by the Ethics Committee
of the Department of Experimental Biomedicine and
Clinical Neurosciences, University of Palermo.
Informed consent to the blood drawing and lumbar
puncture was obtained from all subjects (i.e. ALS and
neurological controls).
PBL and CSF samples
Peripheral venous blood and CSF samples were col-
lected between 8:00 a.m. and 10:00 a.m. from fasted
patients and controls, and labelled to ensure anonym-
ity. CSF was immediately aliquoted and stored at
80°C until analysis. Routine CSF analysis was within
normal range in each patient or control. PBL were iso-
lated using a dextran sedimentation method as
Table 1 Demographic and clinical characteristics of the amyotrophic








(n = 11) P*
Age (years) 62.1  11.05 56.6  15.30 54.3  12.00 0.077




Quantitative data are expressed as mean  SD. *One-way ANOVA
test.
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described by Skoog and Beck [27] and kept frozen at
80°C. Puriﬁed leukocytes were homogenized in ice-
cold lysis buﬀer [10 mM phosphate (pH 7.4), 150 mM
NaCl, 5 mM KCl, 2 mM EDTA, 2 mM EGTA, 0.5%
Triton X-100 and protease inhibitors (2 lg/ml aproti-
nin, 10 lg/ml leupeptin, 5 lg/ml pepstatin)], incubated
in an ice bath for 30 min and centrifuged at 10 000 g
for 10 min at 4°C. The resulting supernatants were
stored at 80°C until western blot analysis.
Western blot analysis
Protein extracts of PBL or CSF (65 or 100 lg of pro-
teins; Bio-Rad Bradford Protein Assay) were separated
by 12% SDS/PAGE and transferred onto PVDF mem-
branes. Membranes blocked with TBS buﬀer plus
0.1% Tween-20 and 5% non-fat milk for 1 h were
incubated with a polyclonal rabbit anti-human (N-
terminal) VAPB antibody (1:400, Proteintech Group
Inc., Chicago, IL, USA) overnight at 4°C. Immuno-
complexes were detected with horseradish-peroxidase-
conjugated anti-rabbit antibody using Super-Signal
West-Pico-Pierce. Membranes were reprobed with an
anti-b-actin antibody (Clone AC-15; Sigma Aldrich,
St. Louis, MO, USA) or an anti-human albumin anti-
body (Santa Cruz, Dallas, TX, USA) to conﬁrm equal
protein loading. In some experiments, a VAPA mouse
anti-human monoclonal antibody (1–132 amino acids,
aa) from R&D Systems (Minneapolis, MN, USA;
Clone # 604101; 1:400) was used. Densitometry was
performed using Chemi-Doc, Quantity-One analysis
(Bio-Rad Laboratories, Segrate, Milam, Italy).
Statistics
The SIGMASTAT 3.5 software package (Systat Soft-
ware Inc., Point Richmond, CA, USA) was used. Data
are expressed as mean  SD and were analysed with
ANOVA followed by a post hoc Neuman–Keuls analysis.
The Mann–Whitney U test was used to evaluate diﬀer-
ences in the median PBL MSP-VAPB/b-actin ratio or
CSF MSP-VAPB/b-albumin ratio between SALS and
neurological controls (NC), and the Kruskal–Wallis
test followed by Dunn’s multiple comparison test. Dif-
ferences between groups were also evaluated using the
Fisher test. Statistical signiﬁcance was set at P < 0.05.
Results
Characterization of VAPB processing products in PBL
and CSF
The topology of the human VAPB protein (243 aa
residues) traces an N-terminal domain (7–124 aa) that
is homologous to the nematode major sperm protein
and thus referred to as the MSP domain, a central
coiled-coil domain (159–196 aa) and a short trans-
membrane anchor at the C-terminal region (220–
243 aa) (UniProt/Swiss-Prot-095292 and Fig. 1). To
identify products containing the N-terminal MSP
domain that were probably generated by VAPB prote-
olytic cleavage, a commercially available anti-human
VAPB antibody raised against an epitope correspond-
ing to the N-terminal region of 31–180 aa residues
(Proteintech Group) was used.
The expression pattern of VAPB and its MSP-con-
taining fragments was initially investigated by western
blot in PBL of healthy controls (HC) and non-ALS
neurological subjects used herein as controls (NC). A
small 30 kDa band, which corresponded to the full-
length protein, and two major bands of approximately
17 kDa and 14 kDa were identiﬁed in both control
groups (Fig. 2a). To optimize sensitivity of our detec-
tion and monitor diﬀerences in the 17 kDa and 14 kDa
bands amongst samples, a lesser amount of protein
extract (65 lg) was used. As shown in Fig. 2b, both
bands were still strongly expressed in PBL but only the
14 kDa band was detected in CSF. This was the exclu-
sive band in CSF and no other bands were detected
even at a higher protein concentration (i.e. 100 lg; data
not shown), with the only exception being a 24 kDa
band noted in a very few cases. Speciﬁcity of bands in
PBL and CSF was proved by VAPB antibody pre-
absorption with the immunogen peptide (Fig. 2c).
Figure 1 Schematic representation of structural domains of human VAPB protein. Positions of VAPB mutations (p.P56S, p.T46I and
p.V234I) and immunogen peptide (31–180 aa) of the wild-type VAPB used to generate the anti-human VAPB antibody (Proteintech
Group Inc.) are shown.
© 2013 The Author(s)
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As VAPA is closely related to VAPB, sharing con-
siderable sequence homology [28], the lack of cross-
reactivity was veriﬁed by analysing COS-1 cell lysates
expressing Myc-tagged VAPA with anti-VAPB anti-
body (Fig. S1). Furthermore, VAPA processing and
secretion in the leukocytes and CSF of control groups
was established using a monoclonal anti-human
VAPA antibody (Fig. 2d). It was found that control
leucocytes expressed full-length VAPA of about
33 kDa and only one other band that approximated
the molecular size of 17 kDa but diﬀered from that of
VAPB as shown by ﬂuorescence-based western blot
analysis (Fig. S2), whilst no band recognized by
VAPA antibody was detected in CSF from NC
patients (n = 10) or from ALS patients (n = 10) (data
not shown).
Altogether, these results are consistent with the
detection of two speciﬁc VAPB processing products
(17 kDa and 14 kDa) in leukocytes and only one in
CSF. The relatively low intensity of the full-length
VAPB detected in PBL extracts of HC and NC, even
at an elevated protein concentration (100 lg), suggests
a high proteolytic processing in these cells. Indeed, in
central nervous system (CNS) tissues of the adult
mouse, having 89.7% homology with VAPB in
humans, there was a higher expression of the full-
length VAPB and faint lower bands compared with
the expression pattern of leukocytes (Fig. S3). On the
other hand, the two identiﬁed bands show the
expected sizes of a cleaved MSP-containing fragment
of 17 kDa previously detected in leukocytes [11] and
of the exact MSP domain with a calculated size of
14 kDa [29].
The expression of VAPB MSP-containing fragments
in PBL (n = 26) and CSF (n = 46) of SALS patients
and controls (n = 22 for both HC and NC PBL;
n = 33 for NC CSF specimens) was then analysed. As
shown in Fig. 3, scatter plot analyses did not reveal
signiﬁcant changes in the expression of either the
17 kDa (Fig. 3a) or 14 kDa (Fig. 3b) fragments in the
PBL of SALS patients compared with controls. When
the CSF 14 kDa MSP was analysed (Fig. 4a and b),
it was found that 29 of the 33 CSF controls (NC-
CSF, 87.9%) expressed the fragment, whereas it was
only detected in 41.3% of SALS patients (P = 0.001,
Fischer exact test; Fig. 4b). By dividing SALS patients
according to the site of onset, the 14 kDa band was
absent in 19/24 (79.2%) patients with bulbar onset
(ALS-B) and in 8/22 (36.3%) patients with spinal
onset (P = 0.006, ALS-B vs. ALS-S, Fischer exact
test; Fig. 4b). These results reveal that a great number
of SALS patients (58.7%) had brain-derived VAPB
processing aﬀected, and the majority of them were
with bulbar onset.
These results were tentatively matched with the
demographic and clinical variables. With the excep-
tion of the site of disease onset, no correlation with
sex, age at onset, disease progression (evaluated by
AARS) and diagnostic delay (data not shown) was
found. It was also veriﬁed that the inclusion of
patients with Alzheimer dementia, spinocerebellar
ataxia and primary progressive aphasia in the NC




Figure 2 Expression of VAPB and VAPA proteins in PBL and
CSF from healthy (HC) and neurological (NC) controls. (a), (b),
(d) Representative immunoblots showing the expression pattern
of VAPB (a), (b) and VAPA (d) identiﬁed in PBL and CSF. (c)
Peptide competition experiments to verify speciﬁcity of the anti-
VAPB antibody. Western blots were carried out with (a) 100 lg
or (b)–(d) 65 lg proteins of extracts. Diﬀerences in the molecu-
lar sizes of VAPB and VAPA bands are reported in leucocytes.
VAPB and VAPA exhibit two close bands that approximate the
molecular size of 17 kDa. In CSF, only the 14 kDa band of
VAPB was identiﬁed in most samples examined, and no VAPA
product was detected; in rare instances, a 24 kDa band of VAPB
(asterisk) was additionally detected.
© 2013 The Author(s)
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Discussion
It has been demonstrated that cleavage products of
VAPB containing the MSP domain are expressed in
PBL of SALS patients and controls with no diﬀer-
ences between them, but the CSF MSP fragment is
largely absent in patients with bulbar onset, thus sug-
gesting a potential role of the VAPB MSP domain in
the pathophysiology of this devastating neurodegener-
ative disorder.
Vesicle-associated membrane-protein-associated pro-
tein B cleavage has been previously described in human
leukocytes and rodent brain tissues [11,22], and secre-
tion of the N-terminal MSP domain in human serum
has been reported as well [11]. Using an antiserum
directed against 31–180 aa residues of human VAPB,
the presence of two bands of approximate sizes 17 kDa
and 14 kDa in PBL and one band of 14 kDa in CSF
from a large number of subjects (including controls
and SALS patients) is shown. The full-length VAPB in
PBL was faintly expressed and it is suspected that
VAPB processing may diﬀer amongst cell types, being
for instance higher in these peripheral cells than in neu-
ral tissues. VAP proteins and their truncated forms are
expressed at diﬀerent levels in rodent CNS tissues and
organs, also increasing with age in the brain [21,22].
VAPB processing is an open question and requires
more investigation.
Based on a 14 kDa expected molecular mass for the
MSP domain [29], it is presumed that the two molecu-
lar weight forms identiﬁed in leukocytes are both
MSP-containing fragments resulting from a diﬀerent
cleavage process, and the CSF 14 kDa peptide is
instead the unique secreted MSP product of brain-
derived VAPB proteolytic processing. Speciﬁc VAPB
cleavage and secretion was conﬁrmed by the lack of
CSF products of the VAPB homologous VAPA. Note
that a band of 24 kDa appeared in a few CSF sam-
ples, either from NC or SALS patients. This suggests
an individual proteolytic processing or alternative
splicing across individuals. The alternative mRNA
transcripts of VAPB identiﬁed so far include VAPC
with a lower molecular mass of 11 kDa [16,29] and
ﬁve new splice variants whose mRNAs are expressed
in the human nervous system but their translation
products have yet to be characterized [30]. These and
our observations are important issues for further
investigation. However, given the limited and unpre-
dictable appearance of this band, it was not consid-
ered in our present analysis.
This study is the ﬁrst showing secretion of an MSP-
containing peptide of VAPB, but not of VAPA, in
human CSF. So far, human VAPB MSP secretion has
been suggested by the homology with the Caenorhabd-
itis elegans and Drosophila MSPs [11,23], and only
Tsuda et al. [11] reported VAPB MSP secretion in
human serum. The mechanism of this secretion still
remains obscure. However, it is shown here that the
secreted MSP correlates with SALS disease. Our
results in fact reveal that the expression of the 17 kDa
and 14 kDa MSP-containing fragments was
unchanged in PBL extracts of SALS patients and con-
trols, but the 14 kDa fragment was absent in the CSF
of more than half of SALS patients compared with
NC. The expression levels of CSF did not correlate
with those of leukocytes and no correlation was found
even in those patients with the lowest expression of
fragments in leukocytes, thus excluding an impairment
of VAPB at the transcriptional level.
A reduction in VAPB expression has been seen in
the post-mortem spinal cord of SALS patients, mostly
marked in the rapidly progressing group who died
within 3 years from diagnosis [15]. Interestingly, it
was found that 79.2% of SALS patients with absent
CSF 14 kDa MSP fragment had bulbar onset. These
observations point to a key role of VAPB in the path-
ogenesis of motor neuron degeneration.
Several lines of evidence support the hypothesis that
pathophysiological mechanisms may diﬀer between
patients with bulbar and spinal onset. For instance, lev-
els of phosphorylated neuroﬁlament heavy-subunit and
growth hormone in CSF and serum are higher in
(a)
(b)
Figure 3 Scatter plots of the expression levels of VAPB MSP
fragments in PBL of SALS patients and controls. Levels of the
17 kDa (a) or 14 kDa (b) fragments are expressed as the ratio
between their intensities and those of b-actin immunoreactive
bands. No signiﬁcant diﬀerences for the two fragments were
found amongst HC, NC and SALS.
© 2013 The Author(s)
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bulbar-onset ALS patients than in the spinal-onset
patients, and CSF erythropoietin levels are lower in
bulbar-onset ALS [31–34]. Age at onset, epidemiologi-
cal and brain metabolism data also strengthen diﬀer-
ences between bulbar- and spinal-onset forms of ALS
[35,36]. Our results indeed support the likelihood of dif-
ferent pathophysiological states in the two conditions.
The MSP domain of VAPB has been suggested to
act as an extracellular ligand for ephrin receptors,
NMDA receptors and LAR-Robo co-receptors, so
having eﬀects on motor neuron survival and muscle
energy metabolism [11,23]. A p.Pro56Ser mutation in
this domain leads to failure of secretion, and this is
supposed to be another possible cause of motor neu-
ron degeneration in certain cases of familial ALS,
such as ALS8 type [11,22,23]. The mutated and
uncleaved VAPB has been suggested to form cytoplas-
mic aggregates in the ER, thus altering its homeostasis
[37]. Interestingly, Qiu et al. [38] have recently sug-
gested that aggregates of the mutated VAPB do not
cause motor neuron degeneration by a gain of toxic-
ity, but a loss of function may be the underlying
mechanism.
VAPB or C9orf72, FUS, TARDP and SOD1 muta-
tions were not found in our ALS cases (L. Conforti,
personal communication). VAPB MSP fragment,
however, was undetected in the CSF of SALS
patients, and in particular in the bulbar-onset group.
It is therefore possible that a tissue-speciﬁc post-trans-
lational failure to produce a cleaved MSP fragment
might contribute to the pathogenesis of this devastat-
ing motor neuron disease.
(a)
(b) (c)
Figure 4 Analyses of the VAPB MSP fragment in CSF from neurological controls (NC) and SALS patients with bulbar (ALS-B) and
spinal onset (ALS-S). (a) Representative immunoblots of the CSF 14 kDa fragment from 15 subjects analysed of each group; albumin
immunoblotting was used to control protein loading. (b), (c) Scatter plots of the expression levels of the CSF VAPB MSP fragment
detected in the samples examined (NC, n = 33; SALS, n = 46; ALS-S, n = 22; ALS-B, n = 24). Western blot analyses of VAPB MSP
were performed in triplicate using the same amount of proteins (65 lg) for each CSF sample and by reprobing membranes with albu-
min antibody. Levels of the 14 kDa fragment result from the ratio of the fragment over albumin density in each sample on western
blotting. (a) *Mann–Withney U test (P < 0.0001, NC vs. SALS); (b) *Kruskal–Wallis test with Dunn’s multiple comparison test
(P < 0.0001, NC vs. ALS-B).
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In conclusion, our study demonstrates a reduced
VAPB MSP fragment expression in the CSF of SALS,
and expands our knowledge of the pathogenic role of
VAPB in this motor neuron disorder. Most bulbar-
onset patients had undetectable VAPB-derived frag-
ment, and this supports the hypothesis that the two
main ALS phenotypes (i.e. bulbar- and spinal-onset
ALS) may at least in part be driven by diverse patho-
physiological mechanisms.
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